Long‐term outcome results of the first tandem autotransplant trial for multiple myeloma

Summary Total Therapy 1, the first tandem autotransplant trial for newly diagnosed patients with multiple myeloma, was designed to increase the frequency of complete response (CR) and thereby extend survival. With a median follow‐up of 12 years, 62 of 231 initially enrolled patients are alive (17% a...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2006-10, Vol.135 (2), p.158-164
Main Authors: Barlogie, Bart, Tricot, Guido J., Van Rhee, Frits, Angtuaco, Edguardo, Walker, Ron, Epstein, Joshua, Shaughnessy, John D., Jagannath, Sundar, Bolejack, Vanessa, Gurley, Jennifer, Hoering, Antje, Vesole, David, Desikan, Raman, Siegel, David, Mehta, Jayesh, Singhal, Seema, Munshi, Nikhil C., Dhodapkar, Madhav, Jenkins, Bonnie, Attal, Michel, Harousseau, Jean‐Luc, Crowley, John
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Disease Progression
Drug Administration Schedule
Epidemiologic Methods
Female
Hematologic and hematopoietic diseases
Hematopoietic Stem Cell Transplantation - methods
high‐dose melphalan
Humans
Immunodeficiencies. Immunoglobulinopathies
Immunoglobulinopathies
Immunopathology
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Male
Medical sciences
Melphalan - administration & dosage
Middle Aged
Multiple Myeloma - drug therapy
Multiple Myeloma - therapy
myeloma
Prognosis
Recurrence
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Total Therapy 1, the first tandem autotransplant trial for newly diagnosed patients with multiple myeloma, was designed to increase the frequency of complete response (CR) and thereby extend survival. With a median follow‐up of 12 years, 62 of 231 initially enrolled patients are alive (17% at 15 years); 31 remain event free (7% at 15 years) including 16 of 94 (41%) that initially achieved CR. Currently alive patients less frequently had cytogenetic abnormalities (CAs) at baseline (P = 0·002), postenrolment (P 
ISSN:0007-1048
1365-2141
DOI:10.1111/j.1365-2141.2006.06271.x